Related references
Note: Only part of the references are listed.Proteomics-driven cancer biomarker discovery: looking to the future
Richard J. Simpson et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2008)
Proteomic profiling of endothelial cells in human lung cancer
Hye-Jeong Park et al.
JOURNAL OF PROTEOME RESEARCH (2008)
Mining the plasma proteome for cancer biomarkers
Samir M. Hanash et al.
NATURE (2008)
Proteomics as a method for early detection of cancer: A review of proteomics, exhaled breath condensate, and lung cancer screening
Dean H. Conrad et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2008)
Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution
Hasmik Keshishian et al.
MOLECULAR & CELLULAR PROTEOMICS (2007)
Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS
Sun-Hee Heo et al.
PROTEOMICS (2007)
The genomic landscapes of human breast and colorectal cancers
Laura D. Wood et al.
SCIENCE (2007)
Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers
Naoki Yanagawa et al.
LUNG CANCER (2007)
A multiple reaction monitoring method for absolute quantification of the human liver alcohol dehydrogenase ADH1C1 isoenzyme
Dariusz J. Janecki et al.
ANALYTICAL BIOCHEMISTRY (2007)
Biomarkers for lung cancer: clinical uses
Alissa K. Greenberg et al.
CURRENT OPINION IN PULMONARY MEDICINE (2007)
Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer
Andrea Ardizzoni et al.
CANCER (2006)
Strategies for plasma proteomic profiling of cancers
Gilbert S. Omenn
PROTEOMICS (2006)
Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer
Ling-Jin Huang et al.
LUNG CANCER (2006)
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Nader Rifai et al.
NATURE BIOTECHNOLOGY (2006)
K-ras mutations in non-small-cell lung carcinoma:: A review
Sarit Aviel-Ronen et al.
CLINICAL LUNG CANCER (2006)
Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer
Rafal Dziadziuszko et al.
CLINICAL CANCER RESEARCH (2006)
Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer
JS Kim et al.
CANCER RESEARCH (2006)
Differential exoprotease activities confer tumor-specific serum peptidome patterns
J Villanueva et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Translational studies for target-based drugs
K Nishio et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Biomarkers in cancer staging, prognosis and treatment selection
JA Ludwig et al.
NATURE REVIEWS CANCER (2005)
Dialanostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer
JH Lee et al.
CHEST (2005)
Lung cancer screening
JL Mulshine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer
T Okamoto et al.
EUROPEAN JOURNAL OF CANCER (2005)
An overview of lung cancer genomics and proteomics
CA Granville et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2005)
CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy
F Barlési et al.
BRITISH JOURNAL OF CANCER (2005)
Predictive factors for survival in surgically resected clinical IA peripheral adenocarcinoma of the lung
Y Sakao et al.
ANNALS OF THORACIC SURGERY (2004)
Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer
F Barlési et al.
RESPIRATORY MEDICINE (2004)
Targeting the checkpoint kinases: Chemosensitization versus chemoprotection
BBS Zhou et al.
NATURE REVIEWS CANCER (2004)
Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA)
NL Anderson et al.
JOURNAL OF PROTEOME RESEARCH (2004)
Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer
S Holdenrieder et al.
CLINICAL CANCER RESEARCH (2004)
Gene-promoter hypermethylation as a biomarker in lung cancer
SA Belinsky
NATURE REVIEWS CANCER (2004)
Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas
VN Senchenko et al.
ONCOGENE (2004)
Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: Analysis of 1,000 consecutive resections for clinical stage I disease
M Okada et al.
ANNALS OF THORACIC SURGERY (2004)
ProGRP:: a new biomarker for small cell lung cancer
R Molina et al.
CLINICAL BIOCHEMISTRY (2004)
Clinical utility of cytokeratins as tumor markers
V Barak et al.
CLINICAL BIOCHEMISTRY (2004)
Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy
P Oh et al.
NATURE (2004)
Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling
WCS Cho et al.
CLINICAL CANCER RESEARCH (2004)
Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death lung cancer in resectable non-small lung cancer
M Pollán et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC)
D Ferrigno et al.
LUNG CANCER (2003)
Clinical equivalence of two cytokeratin markers in non-small cell lung cancer - A study of tissue polypeptide antigen and cytokeratin 19 fragments
G Buccheri et al.
CHEST (2003)
Imatinib mesylate in the treatment of chronic myeloid leukaemia
BJ Druker
EXPERT OPINION ON PHARMACOTHERAPY (2003)
The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up
RM Bremnes et al.
LUNG CANCER (2003)
Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer
JL Pujol et al.
LUNG CANCER (2003)
Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis - Comparison with the main clinical and pathological prognostic factors
R Molina et al.
TUMOR BIOLOGY (2003)
Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: implication for the detection of circulating colon cancer cells
R Hampton et al.
ONCOGENE (2002)
The human plasma proteome - History, character, and diagnostic prospects
NL Anderson et al.
MOLECULAR & CELLULAR PROTEOMICS (2002)
Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers
ER Zabarovsky et al.
ONCOGENE (2002)
Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer
N Reinmuth et al.
LUNG CANCER (2002)
Prognostic value of serum tumor markers in patients with lung cancer
KD Hatzakis et al.
RESPIRATION (2002)
Expression of p15 and p15.5 products in neuroendocrine lung tumours:: relationship with p15INK4b methylation status
L Chaussade et al.
ONCOGENE (2001)
Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients
JL Pujol et al.
LUNG CANCER (2001)
Tissue polypeptide-specific antigen and carcinoembryonic antigen for early prediction of recurrence in lung adenocarcinoma
SS Sun et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2000)
Prognostic factors in advanced non-small cell lung cancer: Elevated serum levels of neuron specific enolase indicate poor prognosis
T Maeda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2000)
Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas
AK Virmani et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Proteomics to study genes and genomes
A Pandey et al.
NATURE (2000)
Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels
K Kashiwabara et al.
CLINICA CHIMICA ACTA (2000)
Share Paper
